MSP3-CRM-Vac4All/ Alhydrogel® Vaccine

NCT ID: NCT05776017

Last Updated: 2023-04-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 465 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-27
• Study Completion Date: 2024-08-31

Brief Summary

Two-arm, randomized, double-blinded and controlled clinical trial to first assess the safety and tolerability of the vaccine in a Phase 1b trial and proceed to assess its efficacy against clinical malaria in young children living in highly seasonal malaria areas of Mali

Detailed Description

This study is designed to be executed in two steps to achieve the primary efficacy objective:

The first step is a Phase 1b safety study, involving injections in a small safety subgroup for each dose before age-de-escalation into the younger age group and then proceeding to the second step of dosing the corresponding injection in the larger Phase 2b efficacy cohort.

Vaccination of the Phase 2b cohort will require an acceptable reactogenicity data over the first week following the corresponding vaccination of the older and younger age groups in the Phase 1 subgroup. The study DSMB will be charged with this review and ensuring that vaccination proceeds only if the reactogenicity profile meet study "go" criteria (Table 1).

The objectives of each phase are:

Phase 1b: The primary objective is to assess the safety and tolerability of the vaccine for each injection. The secondary objective is to evaluate the immune response to the vaccine and safety for up to 12 months after the first dose.

Phase 2b: The primary objective is to assess the efficacy in young children* against clinical malaria** during one transmission season. The timeline for the primary analysis assessment is from 14 days to 6 months after Dose 3.

Should the primary analysis data demonstrate that the vaccine gives good efficacy, a boost vaccination will be programmed to be administered to willing subjects before the start of the subsequent transmission season. The study protocol will be amended with the precise details in this event.

Conditions

Malaria,Falciparum

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Test Vaccine

MSP3-CRM-Vac4All/ Alhydrogel®

Group Type: EXPERIMENTAL

MSP3-CRM-Vac4All/ Alhydrogel®

Intervention Type: BIOLOGICAL

30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant

Control Vaccine

Anti-rabies vaccine

Group Type: ACTIVE_COMPARATOR

Anti-Rabies Vaccine

Intervention Type: BIOLOGICAL

Control vaccine

Interventions

MSP3-CRM-Vac4All/ Alhydrogel®

30 microgram MSP3-CRM-Vac4All protein extemporaneously formulated with Alhydrogel® adjuvant

Intervention Type: BIOLOGICAL

Anti-Rabies Vaccine

Control vaccine

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Children aged 12-59 months years old
• Healthy by medical history, physical examination and laboratory investigation
• Signed/thumb printed informed Consent by guardian/parent
• Resident in the study area villages during the whole trial period

Exclusion Criteria

• Symptoms, physical signs of disease that could interfere with the interpretation of the trial results or compromising the health of the participants
• Immunosuppressive therapy (steroids, immune modulators or immune suppressors) within 3 months prior recruitment. (For corticosteroids, this will mean prednisone, or equivalent, more or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
• Cannot be followed for any social, psychological or geographical reasons.
• Use of any investigational drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use up to 30 days after the third dose.
• Suspected or known hypersensitivity to any of the vaccine components or to previous vaccine.
• Clinically significant laboratory abnormalities on screened blood samples.
• Planned administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of vaccine. An exception, is the receipt of an childhood immunization program or licensed vaccine (measles, oral polio, Hib, meningococcal and combined diphtheria/pertussis/tetanus vaccines) which may be given before or after vaccination*.
• Evidence of chronic or active hepatitis B or C infection
• Presence of chronic illness that, in the judgment of the investigator, would interfere with the study outcomes or pose a threat to the participant's health.
• Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
• History of surgical splenectomy.
• Moderate or severe malnutrition at screening based on clinical judgement.

o (Weight-for-age Z score of less than -3 or other clinical signs of malnutrition).

• Previous participation to a malaria vaccine trial
• Known history of HIV infection

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 59 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Malaria Research and Training Center, Bamako, Mali

OTHER

Sponsor Role: collaborator

Vac4All

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Manamadou Thera, MD

Role: STUDY_DIRECTOR

MRTC, University of Sciences Techniques and Technologies of Bamako, Mali Locations:

Locations

Malaria Research and Training Center (MRTC), University of Sciences Techniques and Technologies of Bamako, Mali

Bamako, , Mali

Site Status: RECRUITING

Countries

Mali

Central Contacts

Zarifah H Reed, MD, MPH

Role: CONTACT

zahussain22@gmail.com

+33695695786

Facility Contacts

Mahamadou Thera, MD

Role: primary

mthera@icermali.org

+223 66 74 09 61

Karim Traore

Role: backup

Karim@icermali.org

+223 66 72 50 63

Other Identifiers

V4ALL/MSP3/009

Identifier Type: -

Identifier Source: org_study_id